Cargando…

Subclinical Pulmonary Involvement in Active IBD Responds to Biologic Therapy

OBJECTIVE: Increased mortality from respiratory diseases was observed in epidemiological studies of patients with ulcerative colitis [UC] as a potentially underestimated extraintestinal manifestation. We therefore investigated the presence of pulmonary manifestations of inflammatory bowel disease [I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ellrichmann, M, Bethge, J, Boesenkoetter, J, Conrad, C, Noth, R, Bahmer, T, Nikolaus, S, Aden, K, Zeissig, S, Schreiber, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521732/ https://www.ncbi.nlm.nih.gov/pubmed/33544122 http://dx.doi.org/10.1093/ecco-jcc/jjab024

Ejemplares similares

Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis
por: Bethge, Johannes, et al.
Publicado: (2017)

Prognostic Factors of Biologic Therapy in Pediatric IBD
por: Buczyńska, Anna, et al.
Publicado: (2022)

The Interplay Between Use of Biological Therapies, Psychological State, and the Microbiome in IBD
por: Tavakoli, Paris, et al.
Publicado: (2022)

Cardiovascular Involvement in Psoriasis, Diagnosing Subclinical Atherosclerosis, Effects of Biological and Non-Biological Therapy: A Literature Review
por: Valaiyaduppu Subas, Sharathshiva, et al.
Publicado: (2020)

Are EPA and DHA Derivatives Involved in IBD Remission?
por: Kikut, Justyna, et al.
Publicado: (2022)

Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2020)

A143 SAFETY OF BIOLOGICAL THERAPIES IN ELDERLY IBD: A SYSTEMATIC REVIEW
por: Golovics, P, et al.
Publicado: (2022)

Biologic therapy is associated with a mild decrease in the rate of hospitalizations in pediatric IBD
por: Berkovitch, Gil, et al.
Publicado: (2021)

Weight and BMI Patterns in a Biologicals-Treated IBD Cohort
por: Kaazan, P., et al.
Publicado: (2022)

Relapse rates after withdrawal versus maintaining biologic therapy in IBD patients with prolonged remission
por: Stoker, Annemay M. H., et al.
Publicado: (2023)

A68 HOW REAL ARE YOUR SURVEY RESPONDENTS? IDENTIFYING FRAUDULENT RESPONDENTS IN ONLINE SURVEYS – A CASE EXAMPLE IN INFLAMMATORY BOWEL DISEASE (IBD)
por: MacDonald, K V, et al.
Publicado: (2023)

Magnetic bead-assisted endoscopic submucosal dissection: a gravity-based traction method for treating large superficial colorectal tumors
por: Ye, Liansong, et al.
Publicado: (2019)

Fr494 THE IMPACT OF VEDOLIZUMAB THERAPY ON COVID-19 OUTCOMES IN ADULT IBD PATIENTS IN THE SECURE-IBD REGISTRY
por: Agrawal, Manasi, et al.
Publicado: (2021)

The Involvement of Immune Semaphorins in the Pathogenesis of Inflammatory Bowel Diseases (IBDs)
por: Vadasz, Zahava, et al.
Publicado: (2015)

Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient
por: Nones, Rodrigo Bremer, et al.
Publicado: (2021)

Editorial: Microbiome in IBD: From Composition to Therapy
por: Zhu, Ruixin, et al.
Publicado: (2021)

Overuse of Tuberculosis Surveillance Testing in Patients With Inflammatory Bowel Disease Compared to Non-IBD Patients on Biologic Therapy
por: Fine, Sean, et al.
Publicado: (2021)

The Impact of PPARγ Genetic Variants on IBD Susceptibility and IBD Disease Course
por: Mwinyi, Jessica, et al.
Publicado: (2012)

Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-IBD gastroenterologists
por: Bilal, Mohammad, et al.
Publicado: (2017)

Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD
por: Soendergaard, Christoffer, et al.
Publicado: (2018)

The Association between Air Pollution and Subclinical Atherosclerosis: Rivera et al. Respond
por: Rivera, Marcela, et al.
Publicado: (2014)

Increased intestinal permeability and tight junction disruption by altered expression and localization of occludin in a murine graft versus host disease model
por: Noth, Rainer, et al.
Publicado: (2011)

Novel inflammatory bowel disease (IBD) specific electronic medical record allows scalable auditing of IBD severity, therapy and complications to show the current unmet need in IBD care
por: Barnes, Alex, et al.
Publicado: (2022)

IBD LIVE Case Series–Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment?
por: Le, Peter N., et al.
Publicado: (2015)

COVID-19 in IBD: The experience of a single tertiary IBD center
por: Rizzello, Fernando, et al.
Publicado: (2021)

Factors Predicting the Adherence to the Therapy of Italian IBD Patients
por: Bucci, Cristina, et al.
Publicado: (2017)

Novel Therapies and Approaches to Inflammatory Bowel Disease (IBD)
por: Furfaro, Federica, et al.
Publicado: (2022)

Clinical outcomes, predictors of prognosis and health economics consequences in IBD patients after discontinuation of the first biological therapy
por: Shivaji, Uday N., et al.
Publicado: (2020)

Zebrafish model for IBD
Publicado: (2011)

IBD considerations in spondyloarthritis
por: Di Jiang, Caroline, et al.
Publicado: (2020)

Subclinical pulmonary abnormalities in juvenile dermatomyositis
por: Sallum, Adriana M, et al.
Publicado: (2014)

The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2021)

Su1482: SCOUT IBD: SURVEILLANCE OF COVID-19 IMPACT ON LONG-TERM OUTCOMES IN IBD
por: Hong, Simon J., et al.
Publicado: (2022)

Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study
por: Bon, Lorenz, et al.
Publicado: (2019)

Risk of Adverse Pregnancy Outcomes for Women with IBD in an Expert IBD Antenatal Clinic
por: Lever, Gillian, et al.
Publicado: (2022)

Optimizing biologic treatment in IBD: objective measures, but when, how and how often?
por: Ben-Horin, Shomron, et al.
Publicado: (2015)

The Usefulness of Serum Vitamin D Levels in the Assessment of IBD Activity and Response to Biologics
por: Valvano, Marco, et al.
Publicado: (2021)

Mycobacterium Avium Subspecies Paratuberculosis Infection and Biological Treatment of IBD: Cause or Consequence?
por: Proietti, E, et al.
Publicado: (2021)

Subclinical Signs of Retinal Involvement in Hereditary Angioedema
por: Triggianese, Paola, et al.
Publicado: (2021)

A Review of Dietary Therapy for IBD and a Vision for the Future
por: Green, Nicole, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s7iq649diqf9nj4dp6bmk46j64